{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T19:07:47Z","timestamp":1771355267006,"version":"3.50.1"},"reference-count":48,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Antifungal prophylaxis remains a mainstay of lung transplantation, given invasive fungal infection is a common and serious complication after lung transplantation. Choice of systemic agent to prevent invasive fungal infection varies between centers and funding of agents remains challenging. Our center has recently changed from posaconazole to a highly bioavailable formulation of itraconazole (SUBA\u00ae\u2010itraconazole) at substantially reduced cost, but safety and toxicity require further assessment. A retrospective study of lung transplant patients receiving systemic antifungal prophylaxis from December 2016 through December 2019 following change from posaconazole to itraconazole as standard practice. 150 patients with lung transplants were managed in this time period, with 88 (59%) receiving at least 1 mold\u2010active triazole during the study period. 48 (58%) of these patients received SUBA\u00ae\u2010itraconazole; 68 (82%) received posaconazole and 10 (12%) received voriconazole. The average cost per patient during the study period was significantly lower on SUBA\u00ae\u2010itraconazole (mean $1548\/patient\/6\u00a0month course) than posaconazole (mean $16\u00a0921.35\/patient\/6\u00a0month course). Target trough concentrations for prophylaxis of itraconazole\u00a0&gt;\u00a00.5\u00a0mg\/L and posaconazole\u00a0&gt;\u00a00.7\u00a0mg\/L were achieved on empiric dosing in 49% and 68% respectively. Overall trough itraconazole (0.50 vs 1.12\u00a0mg\/L, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001) and posaconazole (1.37 vs 2.10\u00a0mg\/L <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001) concentrations were significantly lower in patients with cystic fibrosis. Calcineurin inhibitor dose changes on introduction or cessation were similar for SUBA\u00ae\u2010itraconazole and posaconazole. Breakthrough invasive fungal infection and toxicity were rare. SUBA\u00ae\u2010itraconazole is well\u2010tolerated, associated with rare breakthrough invasive fungal infection, and lower cost. Prospective studies following general introduction are required to determine long\u2010term safety, tolerability, and efficacy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.13587","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T08:27:10Z","timestamp":1613464030000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A novel highly bio\u2010available itraconazole formulation (SUBA\u00ae\u2010Itraconazole) for anti\u2010fungal prophylaxis in lung transplant recipients"],"prefix":"10.1111","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9639-0995","authenticated-orcid":false,"given":"Timothy James","family":"Whitmore","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases Fiona Stanley Hospital Perth WA Australia"},{"name":"Department of Microbiology PathWest Laboratory Medicine WA Perth WA Australia"},{"name":"Department of Respiratory Medicine Fiona Stanley Hospital Perth WA Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meow","family":"Yaw","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Fiona Stanley Hospital Perth WA Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Lavender","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Fiona Stanley Hospital Perth WA Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Musk","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Fiona Stanley Hospital Perth WA Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Boan","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Fiona Stanley Hospital Perth WA Australia"},{"name":"Department of Microbiology PathWest Laboratory Medicine WA Perth WA Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Wrobel","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Fiona Stanley Hospital Perth WA Australia"},{"name":"School of Medicine University of Notre Dame Australia Fremantle WA Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,3]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2019.08.001"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14001"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.02.656"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2016.02.08"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2017.04.011"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1086\/651262"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12854"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.2012.01124"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2016.01.007"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz156"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001050"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2019.01.792"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03375.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2005.05.003"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02734.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0507.1999.00505.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.08.223"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.26.1.5"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061094"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1862"},{"key":"e_1_2_8_22_1","unstructured":"Mayne Pharma International Pty Ltd.Lozanoc Product Information 2014. Available from:https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP\u20102014\u2010PI\u201001749\u20101&d=201901281016933&d=201906291016933&d=202003221016933"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx295"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.12.282"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz303"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S170706"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2010.01373.x"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1397-3142.2003.00103.x"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.12.1730"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00973-15"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01723-18"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-017-0189-6"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1008"},{"key":"e_1_2_8_34_1","volume-title":". Aspergillosis","author":"eTG complete","year":"2019"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-020-01504-6"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1086\/323020"},{"key":"e_1_2_8_37_1","volume-title":"Itraconazole","author":"Australian Department of Health","year":"2020"},{"key":"e_1_2_8_38_1","volume-title":"Posaconazole","author":"Australian Department of Health","year":"2020"},{"key":"e_1_2_8_39_1","volume-title":"R: A language and environment for statistical computing","author":"R Development core team","year":"2020"},{"key":"e_1_2_8_40_1","volume-title":"Common terminology criteria for adverse events (CTCAE)","author":"U.S. Department of Health and Human Services","year":"2017"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa652"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13085"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.3109\/13693786.2010.505203"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199835040-00004"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh175"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1089\/lap.2016.0170"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214539825"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.6.825"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000371"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.13587","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tid.13587","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.13587","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T11:18:46Z","timestamp":1693221526000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.13587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1111\/tid.13587"],"URL":"https:\/\/doi.org\/10.1111\/tid.13587","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"2020-11-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13587"}}